Serum anti-HBs titer was assayed at day time 240

Serum anti-HBs titer was assayed at day time 240. CRP 6 SD 1008 mg/L (aOR: 8.96), hypoalbuminemia (aOR: 6.50) and KT/V 1.2 (aOR: 3.70) were associated with the lack of seroconversion. Summary Half of the individuals in the study experienced either a lack or low protecting vaccine response. Patient-related factors and hemodialysis guidelines were the main factors associated with the lack of anti-HbS seroconversion. These results spotlight the need to maximize doses of vaccine in all individuals. strong class=”kwd-title” Keywords: Hemodialysis, hepatitis B computer virus, vaccination, antibodies seroconversion Intro Hepatitis B computer virus (HBV) is relatively stable in the environment and remains viable for at least one week on environmental surfaces at room heat; its transmission happens through per cutaneous or mucosal exposition to infected blood or body fluids [1]. It is SD 1008 the most causes of cirrhosis and hepatocellular carcinoma in the world [2]. The prevalence of this illness varies worldwide. Higher prevalence is definitely experienced in low-income countries, including those of sub-Saharan Africa (SSA) where HBV illness is hyperendemic. STAT2 Indeed, in the general population, more than 8% of people are hepatitis B surface antigen (HBs Ag) chronic service providers [3]. Five HBV genotypes are more frequently recognized in Africa, A, B, C, D and E genotypes [4]. Individuals on chronic hemodialysis are considered as a high risk group for hepatitis B illness because of many therapeutic methods routinely used in this group increase probability of HBV illness [5]. In this regard, HBs Ag has been recognized in dialysis centers on clamps, scissors, dialysis machine control knobs, and door knobs [6]. Therefore, blood-contaminated surfaces that are not regularly washed and disinfected represent a reservoir for HBV transmission. SD 1008 In addition, dialysis staff members can transmit HBV to individuals from contaminated surfaces by hands, gloves or through use of contaminated products and materials [6]. Thus, controlling the spread of HBV illness in dialysis centers has been one of the major advances in the treatment of individuals with end stage renal disease (ESRD). Today, especially in developed countries, the prevalence of HBs Ag service providers on chronic dialysis offers decreased significantly through preventive steps, such as routine vaccination of individuals and health care workers, regular use of erythropoietin as a substitute for blood transfusions, early serological analysis, isolation of infected individuals, and cleaning and disinfecting methods [7]. Many protocols recommend routine HBV vaccination prior to dialysis with four doses of 40 g each given intramuscularly in the deltoid muscle mass within 0, 1, 2, and 6 months of the procedure [7-9]. However several worldwide studies have shown that one-third of chronic hemodialysis individuals do not respond SD 1008 properly to immunization [7, 10, 11]. The decrease in immunity observed in chronic hemodialysis individuals plays an important role in explaining this non-response [12]. Few studies have examined the effectiveness SD 1008 of HBV vaccination in SSA chronic hemodialysis individuals [13, 14]. Several specificities can influence the HBV vaccine response with this population. Indeed chronic kidney disease is usually recognized very late, at stage requiring dialysis in emergency; in addition, individuals generally have many comorbidities and present uremic syndrome that may reduce their immunity [15]. More often, individuals who have to support themselves their medical care cannot afford the cost of double dose of HBV vaccine. Consequently, in DR Congo, many centers usually provide a single-dose routine to HD individuals, unless they.